3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Enrolling by invitation
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
16
CNS
8
Sarcoma
2
Head & Neck
2
Gastrointestinal
2
Dermatologic
2
Thoracic
1
Lymphoid
1
Breast
1
Conditions
Estrogen Receptor Positive Breast Cancer
1
Interventions
Trastuzumab
692
Paclitaxel
678
Cyclophosphamide
634
Docetaxel
553
Capecitabine
467
Letrozole
407
Carboplatin
392
Fulvestrant
377
Doxorubicin
330
Tamoxifen
288
pembrolizumab
270
Anastrozole
252
Epirubicin
249
exemestane
238
pertuzumab
226
Bevacizumab
214
Radiotherapy
213
Gemcitabine
211
Vinorelbine
188
palbociclib
183
Lapatinib
175
130-nm albumin-bound paclitaxel
168
Albumin-Bound Paclitaxel
156
Exercise
147
Magnetic Resonance Spectroscopy
145
eribulin
144
Taxes
134
Fluorouracil
131
Everolimus
118
Cisplatin
117
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Transurethral Resection of Bladder
×
Breast
×
Clear all
NCT06629233
2025-08-29
Tn-Miner
University Ghent
Phase NA
Enrolling by invitation
36 enrolled